GSK and Chroma Therapeutics form alliance to develop novel macrophage-targeted drugs
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (LSE: GSK) and Chroma Therapeutics Limited announced a collaboration to develop macrophage-targeted compounds using Chroma's proprietary esterase-sensitive motif (ESM) technology, which adds amino acid esters to compounds with the aim of targeting the compounds to specific cells in the inflammatory disease process.
New biological therapy Ilaris® approved in US
- Details
- Category: Novartis
The US Food and Drug Administration (FDA) has approved Ilaris® (canakinumab) for the treatment of children and adults with cryopyrin-associated periodic syndrome (CAPS), which includes a number of rare but life-long auto-inflammatory disorders with debilitating symptoms and limited treatment options[1],[2],[3],[4].
Nycomed receives Marketing Authorization for Pantoprazole 20mg OTC from European Commission
- Details
- Category: Nycomed
Nycomed received marketing authorisation from the European Commission for five applications: PANTOZOL Control®, PANTOLOC Control®, PANTECTA Control®, SOMAC Control® and CONTROLOC Control®. This new OTC medication is intended for short-term treatment of reflux symptoms (e.g. heartburn, acid regurgitation) in adults as a medicinal product not subject to medical prescription.
GSK announces a strategic alliance with Dr. Reddy's Laboratories Ltd
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline plc (GSK) has announced an agreement with Dr. Reddy's Laboratories Ltd (Dr. Reddy's) to develop and market selected products across an extensive number of emerging markets, excluding India.
Abbott Initiates Trial of Next-Generation XIENCE PRIME(TM) Drug Eluting Stent
- Details
- Category: Abbott
Abbott (NYSE: ABT) has announced the initiation of SPIRIT PRIME, a clinical trial to study the performance of the company's next-generation XIENCE PRIME(TM) Everolimus Eluting Coronary Stent System, currently an investigational device, for the
treatment of coronary artery disease. Results from SPIRIT PRIME will be used to support the regulatory filing for XIENCE PRIME in the United States.
Boehringer Ingelheim and Vitae Pharmaceuticals announce a major collaboration
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim and Vitae Pharmaceuticals, Inc., announced today that they have entered into a significant worldwide collaboration to research and develop beta-secretase (BACE) inhibitors for the treatment of Alzheimer's disease. Current therapies for Alzheimer's disease can improve symptoms, but do not affect the progression of the disease.
Eli Lilly and Company Announces New Drug Discovery Initiative
- Details
- Category: Eli Lilly and Company
Goal is to foster open collaboration between Lilly and global laboratory researchers
Alzheimer's disease. Cancer. Diabetes. Osteoporosis.
These are the diseases for which Eli Lilly and Company will be engaging researchers from around the world in a new and unique drug discovery initiative.
Alzheimer's disease. Cancer. Diabetes. Osteoporosis.
These are the diseases for which Eli Lilly and Company will be engaging researchers from around the world in a new and unique drug discovery initiative.
More Pharma News ...
- Novartis demonstrates capabilities of cell-based technology for production of A(H1N1) vaccine
- Genzyme Receives European Approval of Renvela for Patients with Chronic Kidney Disease
- Abbott Announces Launch of Next-Generation Embolic Protection System
- Favourable Vote from FDA Advisory Committee on Seroquel Paediatric Applications
- Takeda to Revise Timing of Alogliptin and Alogliptin/ACTOS MAA Filing in Europe
- GSK and Shenzhen Neptunus create new alliance to develop and manufacture influenza vaccines in China
- Sanofi-aventis to strengthen Insulin Production Capacities